Lafutidine

Jump to: navigation, search

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443919033 | IUPAC_name = 2-[(2-furylmethyl)sulfinyl]-N-((2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy}but-2-en-1-yl)acetamide | image = Lafutidine.png | width = 250

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ☑Y | CAS_number = 118288-08-7 | ATC_prefix = A02 | ATC_suffix = BA08 | ATC_supplemental = | PubChem = 5282136 | DrugBank_Ref =  ☑Y | DrugBank = | UNII_Ref =  ☑Y | UNII = 49S4O7ADLC | KEGG_Ref =  ☑Y | KEGG = D01131 | ChemSpiderID_Ref =  ☒N | ChemSpiderID = 4445337

| chemical_formula = | C=22 | H=29 | N=3 | O=4 | S=1 | molecular_weight = 431.54 g/mol | smiles = C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)C[S+](CC3=CC=CO3)[O-] | InChI = 1/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | InChIKey = KMZQAVXSMUKBPD-DJWKRKHSBS | StdInChI_Ref =  ☒N | StdInChI = 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | StdInChIKey_Ref =  ☒N | StdInChIKey = KMZQAVXSMUKBPD-DJWKRKHSSA-N }}

WikiDoc Resources for Lafutidine

Articles

Most recent articles on Lafutidine

Most cited articles on Lafutidine

Review articles on Lafutidine

Articles on Lafutidine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lafutidine

Images of Lafutidine

Photos of Lafutidine

Podcasts & MP3s on Lafutidine

Videos on Lafutidine

Evidence Based Medicine

Cochrane Collaboration on Lafutidine

Bandolier on Lafutidine

TRIP on Lafutidine

Clinical Trials

Ongoing Trials on Lafutidine at Clinical Trials.gov

Trial results on Lafutidine

Clinical Trials on Lafutidine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lafutidine

NICE Guidance on Lafutidine

NHS PRODIGY Guidance

FDA on Lafutidine

CDC on Lafutidine

Books

Books on Lafutidine

News

Lafutidine in the news

Be alerted to news on Lafutidine

News trends on Lafutidine

Commentary

Blogs on Lafutidine

Definitions

Definitions of Lafutidine

Patient Resources / Community

Patient resources on Lafutidine

Discussion groups on Lafutidine

Patient Handouts on Lafutidine

Directions to Hospitals Treating Lafutidine

Risk calculators and risk factors for Lafutidine

Healthcare Provider Resources

Symptoms of Lafutidine

Causes & Risk Factors for Lafutidine

Diagnostic studies for Lafutidine

Treatment of Lafutidine

Continuing Medical Education (CME)

CME Programs on Lafutidine

International

Lafutidine en Espanol

Lafutidine en Francais

Business

Lafutidine in the Marketplace

Patents on Lafutidine

Experimental / Informatics

List of terms related to Lafutidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lafutidine (INN) is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use

Lafutidine is used to treat gastric ulcers, duodenal ulcers, stomal ulcers, wounds in the lining of the stomach associated with acute gastritis and with acute exacerbation of chronic gastritis.[1][2]

Adverse effects

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea or vomiting and dizziness.[2]

Mechanisms of action

Like other H2 receptor antagonists it prevents the secretion of gastric acid.[2] It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.[2]

History

It is marketed in Japan as Stogar by UCB[1] and in India as Lafaxid by Zuventus Healthcare.[2]

References

  1. 1.0 1.1 UCB Japan Revised: April 2005 Stogar tablets
  2. 2.0 2.1 2.2 2.3 2.4 Zuventus Healthcare Ltd. India Lafaxid tablets

Linked-in.jpg